Premium
Macrophage inhibitor factor (MIF) in cutaneous lymphoproliferative diseases
Author(s) -
UMBERT PABLO,
BELCHER RICHARD W.,
WINKELMANN R.K.
Publication year - 1976
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1976.tb00856.x
Subject(s) - mycosis fungoides , medicine , lymphoma , cutaneous t cell lymphoma , stage (stratigraphy) , macrophage migration inhibitory factor , lymphoproliferative disorders , dermatology , macrophage , cutaneous lymphoma , immunology , pathology , biology , cytokine , paleontology , biochemistry , in vitro
SUMMARY Macrophage migration inhibitor factor (MIF) activity in the sera of patients with mycosis fungoides, Sezary syndrome, and cutaneous lymphoma was observed in the sera of eight of the ten patients with stage II (infiltrative) mycosis fungoides, but in only one of the eight patients with stage I and in neither of the two patients with stage III mycosis fungoides. Two of the three patients with Sezary syndrome had MIF in the serum. No MIF was observed in cutaneous lymphoma. These data support the concept that Sezary syndrome and mycosis fungoides are T‐cell diseases, and transitional, pre‐lymphomatous diseases.